Dextroamphetamine Patent Expiration

Dextroamphetamine is Used for treating Attention Deficit Hyperactivity Disorder (ADHD) with a transdermal amphetamine composition. It was first introduced by Noven Pharmaceuticals Inc in its drug Xelstrym on Mar 22, 2022.


Dextroamphetamine Patents

Given below is the list of patents protecting Dextroamphetamine, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Xelstrym US11559501 Transdermal amphetamine compositions with low levels of carbamate Jan 06, 2042 Noven Pharms Inc
Xelstrym US8591941 Transdermal drug delivery device including an occlusive backing Oct 07, 2025 Noven Pharms Inc
Xelstrym US8632802 Device for transdermal administration of drugs including acrylic polymers Oct 07, 2025 Noven Pharms Inc
Xelstrym US9034370 Device for transdermal administration of drugs including acrylic polymers Oct 07, 2025 Noven Pharms Inc
Xelstrym US9456993 Compositions and methods for transdermal delivery of amphetamine Oct 24, 2033 Noven Pharms Inc
Xelstrym US9474722 Compositions and methods for transdermal delivery of amphetamine Oct 24, 2033 Noven Pharms Inc


Coming Soon

Patent Strength Analyzer

Will this be useful for you?

YesNo

Thank you for your response 🥳